BridgeBio Pharma (BBIO) Cash from Financing Activities (2018 - 2026)

BridgeBio Pharma's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $549.9 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 811.5% year-over-year to $549.9 million; the TTM figure through Mar 2026 stood at $848.9 million (up 60.39% YoY), while the FY2025 annual figure was $359.3 million, down 52.0% from the prior year.
• Cash from Financing Activities came in at $549.9 million for Q1 2026 at BridgeBio Pharma, up from -$2.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $549.9 million in Q1 2026 to a low of -$20.8 million in Q2 2022.
• A 5-year average of $123.3 million and a median of $1.4 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 1395.04% in 2022 and soared 94005.62% in 2023, its largest moves.
• BridgeBio Pharma's Cash from Financing Activities stood at $6.4 million in 2022, then slumped by 170.93% to -$4.5 million in 2023, then soared by 10578.24% to $473.9 million in 2024, then sank by 100.46% to -$2.2 million in 2025, then jumped by 25301.28% to $549.9 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $549.9 million, -$2.2 million, and -$894000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison